|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 212.94 USD | -0.38% |
|
+1.66% | -7.23% |
| 05-15 | Mubadala Investment Co PJSC raises share stake in AbbVie, Match Group, cuts in CVS Health | RE |
| 05-15 | Evercore ISI Adjusts Price Target on AbbVie to $235 From $236, Maintains Outperform Rating | MT |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B | |||||
Total Revenues | 56.2B | 58.05B | 54.32B | 56.33B | 61.16B | |||||
Cost of Goods Sold, Total | 17.31B | 16.53B | 16.73B | 16.69B | 17.36B | |||||
Gross Profit | 38.88B | 41.53B | 37.59B | 39.64B | 43.8B | |||||
Selling General & Admin Expenses, Total | 11.87B | 12.08B | 12.9B | 13.19B | 13.64B | |||||
R&D Expenses | 6.98B | 6.49B | 7.04B | 8.13B | 9.07B | |||||
Other Operating Expenses | 500M | -1M | -10M | -7M | -24M | |||||
Other Operating Expenses, Total | 19.35B | 18.57B | 19.93B | 21.31B | 22.69B | |||||
Operating Income | 19.53B | 22.96B | 17.66B | 18.33B | 21.12B | |||||
Interest Expense, Total | -2.42B | -2.23B | -2.22B | -2.81B | -2.89B | |||||
Interest And Investment Income | 39M | 186M | 540M | 648M | 266M | |||||
Net Interest Expenses | -2.38B | -2.04B | -1.68B | -2.16B | -2.63B | |||||
Currency Exchange Gains (Loss) | -51M | -148M | -146M | -21M | -58M | |||||
Other Non Operating Income (Expenses) | 55M | 142M | 190M | 271M | 403M | |||||
EBT, Excl. Unusual Items | 17.15B | 20.91B | 16.02B | 16.42B | 18.83B | |||||
Merger & Related Restructuring Charges | -587M | -768M | -119M | -792M | -95M | |||||
Gain (Loss) On Sale Of Investments | - | - | - | - | - | |||||
Gain (Loss) On Sale Of Assets | 68M | 172M | - | - | - | |||||
Asset Writedown | - | -876M | -4.23B | -4.48B | -847M | |||||
In Process R&D Expenses | -962M | -697M | -778M | -2.76B | -5.02B | |||||
Legal Settlements | - | -2.5B | 485M | -910M | - | |||||
Other Unusual Items | -2.68B | -2.76B | -5.13B | -3.77B | -6.28B | |||||
EBT, Incl. Unusual Items | 12.99B | 13.48B | 6.25B | 3.72B | 6.6B | |||||
Income Tax Expense | 1.44B | 1.63B | 1.38B | -570M | 2.36B | |||||
Earnings From Continuing Operations | 11.55B | 11.84B | 4.87B | 4.29B | 4.23B | |||||
Net Income to Company | 11.55B | 11.84B | 4.87B | 4.29B | 4.23B | |||||
Minority Interest | -7M | -9M | -10M | -8M | -7M | |||||
Net Income - (IS) | 11.54B | 11.84B | 4.86B | 4.28B | 4.23B | |||||
Preferred Dividend and Other Adjustments | 74M | 54M | 43M | 40M | 40M | |||||
Net Income to Common Incl Extra Items | 11.47B | 11.78B | 4.82B | 4.24B | 4.19B | |||||
Net Income to Common Excl. Extra Items | 11.47B | 11.78B | 4.82B | 4.24B | 4.19B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 6.48 | 6.65 | 2.73 | 2.4 | 2.37 | |||||
Basic EPS - Continuing Operations | 6.48 | 6.65 | 2.73 | 2.4 | 2.37 | |||||
Basic Weighted Average Shares Outstanding | 1.77B | 1.77B | 1.77B | 1.77B | 1.77B | |||||
Net EPS - Diluted | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | |||||
Diluted EPS - Continuing Operations | 6.45 | 6.63 | 2.72 | 2.39 | 2.36 | |||||
Diluted Weighted Average Shares Outstanding | 1.78B | 1.78B | 1.77B | 1.77B | 1.77B | |||||
Normalized Basic EPS | 6.05 | 7.37 | 5.66 | 5.8 | 6.65 | |||||
Normalized Diluted EPS | 6.03 | 7.34 | 5.64 | 5.78 | 6.63 | |||||
Dividend Per Share | 5.31 | 5.71 | 5.99 | 6.29 | 6.65 | |||||
Payout Ratio | 80.24 | 84.85 | 216.72 | 257.71 | 275.84 | |||||
American Depositary Receipts Ratio (ADR) | 1 | 1 | 1 | 1 | 1 | |||||
Supplemental Items | ||||||||||
EBITDA | 28.05B | 31.42B | 26.36B | 26.72B | 29.25B | |||||
EBITA | 27.25B | 30.65B | 25.61B | 25.95B | 28.49B | |||||
EBIT | 19.53B | 22.96B | 17.66B | 18.33B | 21.12B | |||||
EBITDAR | 28.4B | 31.76B | 26.66B | 27.06B | 29.65B | |||||
Effective Tax Rate - (Ratio) | 11.09 | 12.11 | 22.03 | -15.34 | 35.83 | |||||
Current Domestic Taxes | 1.99B | 2.65B | 3.27B | -331M | 1.23B | |||||
Current Foreign Taxes | 351M | 916M | 994M | 1.21B | 1.63B | |||||
Total Current Taxes | 2.34B | 3.56B | 4.27B | 879M | 2.86B | |||||
Deferred Domestic Taxes | -839M | -1.51B | -2.32B | -1.3B | -61M | |||||
Deferred Foreign Taxes | -59M | -419M | -565M | -146M | -431M | |||||
Total Deferred Taxes | -898M | -1.93B | -2.89B | -1.45B | -492M | |||||
Normalized Net Income | 10.71B | 13.06B | 10B | 10.26B | 11.76B | |||||
Interest Capitalized | - | - | - | - | - | |||||
Interest on Long-Term Debt | - | - | - | 2.81B | - | |||||
Non-Cash Pension Expense | -136M | -182M | -274M | -282M | -317M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 2.1B | 2B | 2.2B | 2.1B | 2.1B | |||||
Selling and Marketing Expenses | 2.1B | 2B | 2.2B | 2.1B | 2.1B | |||||
Research And Development Expense From Footnotes | 8.05B | 7.21B | 8.45B | 15.55B | 14.11B | |||||
Net Rental Expense, Total | 353M | 339M | 305M | 347M | 392M | |||||
Imputed Operating Lease Interest Expense | 83.09M | 85.07M | 86.71M | 121M | 133M | |||||
Imputed Operating Lease Depreciation | 270M | 254M | 218M | 226M | 259M | |||||
Stock-Based Comp., COGS (Total) | 46M | 38M | 46M | 91M | 52M | |||||
Stock-Based Comp., R&D Exp. (Total) | 226M | 232M | 278M | 525M | 414M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 420M | 401M | 423M | 805M | 584M | |||||
Total Stock-Based Compensation | 692M | 671M | 747M | 1.42B | 1.05B |
- Stock Market
- Equities
- ABBV Stock
- Financials AbbVie Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















